Consun Pharmaceutical Group Limited

Equities

1681

KYG2524A1031

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 am EDT 5-day change 1st Jan Change
5.67 HKD -0.87% Intraday chart for Consun Pharmaceutical Group Limited +1.61% +18.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit MT
Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024 CI
Consun Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Consun Pharmaceutical Group Limited Announces Board and Committee Changes CI
Consun Pharma CEO Steps Down MT
Consun Pharmaceutical Group Limited Announces CEO Changes CI
Consun Pharmaceutical Group Limited Announces Management Changes CI
Consun Pharmaceutical's Unit Starts Construction of Second Chinese Medicine Granule Plant MT
Consun Pharmaceutical's H1 Profit Rises on Higher Revenue MT
Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 20 September 2023 CI
Consun Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2022 CI
Consun Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2022 CI
Chinese Regulator Approves Consun Pharmaceutical's Clinical Trial for Kidney Disease Treatment MT
Consun Pharmaceutical Group Limited Receives Approval for Clinical Trial of Drug for SK-07 Injection CI
Consun Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Consun Pharmaceutical Group Limited Proposes to Pay A Final Dividend for the Year Ended December 31, 2022, Payable on or About June 21, 2023 CI
Consun Pharmaceutical Group Sees Surge in 2022 First-Half Profit MT
Consun Pharmaceutical's H1 Profit Rises on Higher Revenue MT
Consun Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Wanbangde Pharma in Talks to Buy Controlling Stake in Consun Pharma MT
Consun Pharmaceutical Group Completes First Automatic Production Line of Chinese Medicine Granules MT
Consun Pharmaceutical Group Limited, A Wholly-Owned Subsidiary of Consun Pharmaceutical Co., Ltd Holds A Trial Production Ceremony in Plant No. 8, Area A05, Horgos Comprehensive Bonded Zone, Yili Kazakh CI
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2021 CI
Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on or About 17 June 2022 CI
Chart Consun Pharmaceutical Group Limited
More charts
Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.249 CNY
Average target price
7.272 CNY
Spread / Average Target
+38.54%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 1681 Stock
  4. News Consun Pharmaceutical Group Limited
  5. Consun Pharmaceutical Group Completes First Automatic Production Line of Chinese Medicine Granules